Hangzhou Tigermed Consulting Co., Ltd. (Tigermed; HKEX: 03347) published its 2025 Sustainability Report, detailing strengthened ESG governance, new climate commitments and solid financial results for the year.
Tigermed’s Board-level Compliance and ESG Committee now oversees a comprehensive framework that integrates climate, compliance and stakeholder engagement. All directors and senior managers completed ESG training, and 20 percent of the general manager’s annual compensation is tied to ESG performance.
Climate strategy advanced markedly. The Science Based Targets initiative (SBTi) has validated Tigermed’s goals to cut absolute Scope 1 and 2 greenhouse-gas emissions 42 percent and key Scope 3 categories 25 percent by 2030 from a 2023 baseline. During 2025, Scope 1 emissions were 94.86 tCO₂e and market-based Scope 2 emissions 2,753.83 tCO₂e, equivalent to 0.32 tCO₂e per employee. The company began installing a 93.6 kW rooftop photovoltaic system at its Hangzhou headquarters, introduced LED retrofits and launched rain-water harvesting.
Tigermed’s ESG ratings improved: MSCI raised the company to its highest AAA level; the Shenzhen Stock Exchange maintained Tigermed’s CNI ESG AAA rating; and the CDP climate score stood at “B”.
On the social front, women represented 84 percent of employees and 54 percent of senior management. All staff received compliance and quality-system training, while average training hours reached 52.90. The internal mobility rate was 16.26 percent, supported by a new Competency Framework and an “Efficiency Pioneers” talent program.
Supplier oversight intensified: 78.13 percent of suppliers have signed the Tigermed Supplier Code of Conduct. Eight high-risk suppliers underwent on-site quality audits, and the company reported zero cases of corruption, anti-trust or marketing non-compliance.
Innovation remained a core theme. Six new self-developed projects were launched, including the Taya AI Medical Writing Platform and expanded digital/decentralized clinical-trial (DCT) services. Tigermed’s global network now spans 42 countries after the acquisition of Japan-based Micron and a collaboration agreement with Africare Biopharma.
Financially, net profit attributable to shareholders reached RMB 887.89 million on revenue of RMB ? (not disclosed), while taxes paid totaled RMB 391.73 million. A cash dividend of RMB 1.26 per 10 shares was proposed, supported by cash reserves generated from operations.
Tigermed invested RMB 3.73 million in public-welfare programmes, issued a new ethical-AI guideline and maintained 100 percent resolution of compliance reports, underscoring its commitment to “Advance human health through delivery excellence.”